Modulation of fetal hemoglobin in sickle cell anemia.
A partial understanding of the pathophysiology of sickle cell disease has suggested one means of treatment-increasing the distribution and concentration of fetal hemoglobin in sickle erythrocytes. Although this can be accomplished clinically with drugs like hydroxyurea, a complete understanding of the molecular and cellular basis of fetal hemoglobin regulation may suggest new and better ways of attaining this goal.
Steinberg
M H
MH
G.V. (Sonny) Montgomery Department of Veterans Affairs Medical Center, Jackson, MS 39216, USA. msteinberg@medicine.bu.edu
D000755:Anemia, Sickle Cell / Q000097:blood / Q000188:drug therapy / Q000235:genetics*; D000818:Animals; D004912:Erythrocytes / Q000187:drug effects; D005319:Fetal Hemoglobin / Q000187:drug effects / Q000235:genetics / Q000378:metabolism*; D018507:Gene Expression Regulation, Developmental / Q000187:drug effects; D006801:Humans
D005319:Fetal Hemoglobin